Breathe Well-being vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
Gurugram India YC W20 digital therapeutics for diabetes/PCOD/thyroid/hypertension reversal serving 150M Indian chronic disease patients; $12.9M total (Accel/General Catalyst Series A 2021 + ₹50Cr pre-Series B 2023) competing with Twin Health.
About
Breathe Well-being is a Gurugram, India-based digital therapeutics platform — backed by Y Combinator (W20) with $12.9 million in total funding including a ₹50 crore ($6 million) pre-Series B in 2023 and a $5.5 million Series A in August 2021 led by Accel with General Catalyst, 3one4 Capital, and Scott Shleifer — providing Indians with clinically validated digital programs for reversing and managing Type 2 diabetes, PCOD (polycystic ovarian disease), thyroid disorders, and hypertension through structured weight loss programs combining personalized nutrition coaching, behavioral change support, and continuous glucose monitoring. Founded in 2020 with a mission to help 1 million Indians reverse Type 2 diabetes by 2025, Breathe targets India's 150 million chronic lifestyle disease patients.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.